Pack-years of cigarette smoking as a prognostic factor in patients with stage IIIB/ IV nonsmall cell lung cancer

Cancer

Volumn 116, Issue 3, 2010, Pages 670-675

  Janjigian, Yelena Y ^a   McDonnell, Kevin ^a   Kris, Mark G ^a   Shen, Ronglai ^a   Sima, Camelia S ^a   Bach, Peter B ^a   Rizvi, Naiyer A ^a   Riely, Gregory J ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Cigarettes; Nonsmall cell lung cancer; Pack years; Prognostic factor; Smoking history; Survival

Indexed keywords

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER SURVIVAL; CIGARETTE SMOKING; FEMALE; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; QUESTIONNAIRE; WEIGHT REDUCTION;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, NON-SMALL-CELL LUNG; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; SMOKING; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 76249106679     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.24813     Document Type: Article

References (29)

1. Sobue T, Suzuki T, Fujimoto I, et al. Prognostic factors for surgically treated lung adenocarcinoma patients, with special reference to smoking habit. Jpn J Cancer Res. 1991;82:33-39.
2. Fujisawa T, Iizasa T, Saitoh Y, et al. Smoking before surgery predicts poor long-term survival in patients with stage I non-small-cell lung carcinomas. J Clin Oncol. 1999;17:2086-2091.
3. Martins SJ, Pereira JR. Clinical factors and prognosis in non-small cell lung cancer. Am J Clin Oncol. 1999;22:453-457.
4. Myrdal G, Lambe M, Gustafsson G, et al. Survival in primary lung cancer potentially cured by operation: influence of tumor stage and clinical characteristics. Ann Thorac Surg. 2003;75:356-363.
5. Tan YK, Wee TC, Koh WP, et al. Survival among Chinese women with lung cancer in Singapore: a comparison by stage, histology and smoking status. Lung Cancer. 2003;40: 237-246.
6. Tammemagi CM, Neslund-Dudas C, Simoff M, et al. Smoking and lung cancer survival: the role of comorbidity and treatment. Chest. 2004;125:27-37.
7. Toh CK, Wong EH, Lim WT, et al. The impact of smoking status on the behavior and survival outcome of patients with advanced non-small cell lung cancer: a retrospective analysis. Chest. 2004;126:1750-1756.
8. Nordquist LT, Simon GR, Cantor A, et al. Improved survival in never-smokers vs current smokers with primary adenocarcinoma of the lung. Chest. 2004;126:347-351.
9. Sardari Nia P, Weyler J, Colpaert C, et al. Prognostic value of smoking status in operated non-small cell lung cancer. Lung Cancer. 2005;47:351-359.
10. Ebbert JO, Williams BA, Sun Z, et al. Duration of smoking abstinence as a predictor for non-small-cell lung cancer survival in women. Lung Cancer. 2005;47:165-172.
11. Toh CK, Gao F, Lim WT, et al. Never-smokers with lung cancer: epidemiologic evidence of a distinct disease entity. J Clin Oncol. 2006;24:2245-2251.
12. Yoshino I, Kawano D, Oba T, et al. Smoking status as a prognostic factor in patients with stage I pulmonary adenocarcinoma. Ann Thorac Surg. 2006;81:1189-1193.
13. Tsao AS, Liu D, Lee JJ, et al. Smoking affects treatment outcome in patients with advanced nonsmall cell lung cancer. Cancer. 2006;106:2428-2436.
14. Sawabata N, Miyoshi S, Matsumura A, et al. Prognosis of smokers following resection of pathological stage I non-small-cell lung carcinoma. Gen Thorac Cardiovasc Surg. 2007;55:420-424.
15. Bryant A, Cerfolio RJ. Differences in epidemiology, histology, and survival between cigarette smokers and never-smokers who develop non-small cell lung cancer. Chest. 2007; 132:185-192.
16. Yano T, Miura N, Takenaka T, et al. Never-smoking non-small cell lung cancer as a separate entity: clinicopathologic features and survival. Cancer. 2008;113:1012-1018.
17. Pham D, Kris MG, Riely GJ, et al. Use of cigarette-smoking history to estimate the likelihood of mutations in epidermal growth factor receptor gene exons 19 and 21 in lung adenocarcinomas. J Clin Oncol. 2006;24:1700-1704.
18. Mok TS, Wu Y-L, Thongprasert S, et al. Gefitinib or carboplatin- paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009;361:947-957.
19. Paz-Ares L, Sanchez JM, Garcia-Velasco A, et al. A prospective phase II trial of erlotinib in advanced non-small cell lung cancer (NSCLC) patients (p) with mutations in the tyrosine kinase (TK) domain of the epidermal growth factor receptor (EGFR). J Clin Oncol (Meeting Abstracts). 2006;24:7020.
20. Pignon JP, Tribodet H, Scagliotti GV, et al. Lung adjuvant cisplatin evaluation (LACE): a pooled analysis of five randomized clinical trials including 4,584 patients. J Clin Oncol (Meeting Abstracts). 2006;24:7008.
21. Sunaga N, YanagitaniN, Kaira K, et al. Phase II study of the efficacy of gefitinib in patients with non-small cell lung cancer with the EGFR mutations. J Clin Oncol (Meeting Abstracts). 2006; 24:7183.
22. Sutani A, Nagai Y, Udagawa K, et al. Phase II study of gefitinib for non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) gene mutations detected by PNALNA PCR clamp. J ClinOncol (Meeting Abstracts). 2006;24:7076.
23. Eberhard DA, Johnson BE, Amler LC, et al. Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J Clin Oncol. 2005;2:857.
24. Mountain CF. Revisions in the International System for Staging Lung Cancer. Chest. 1997;111:1710-1717.
25. Long-term survivors in metastatic non-small-cell lung cancer: an Eastern Cooperative Oncology Group Study. J Clin Oncol. 1986;4:702-709.
26. O'Connell JP, Kris MG, Gralla RJ, et al. Frequency and prognostic importance of pretreatment clinical characteristics in patients with advanced non-small-cell lung cancer treated with combination chemotherapy. J Clin Oncol. 1986;4: 1604-1614.
27. Miller VA, Kris MG, Shah N, et al. Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer. J Clin Oncol. 2004;22:1103-1109.
28. Scagliotti GV, Parikh P, von Pawel J, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol. 2008;26:3543-3551.
29. Marks JL, Broderick S, Zhou Q, et al. Prognostic and therapeutic implications of EGFR and KRAS mutations in resected lung adenocarcinoma. J Thorac Oncol. 2008;3:111-116.